Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. - Wikidata - awgldk - TriplyDB

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.

http://www.wikidata.org/entity/Q35846504

about

Optimizing treatment success in multiple sclerosis Imaging as an Outcome Measure in Multiple Sclerosis.Outcome Measures in Clinical Trials for Multiple Sclerosis.Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis.The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis.Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.Defining Disease Activity and Response to Therapy in MS.MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.Long-term evolution of multiple sclerosis disability in the treatment era.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients.Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.No evidence of disease activity in multiple sclerosis patients.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Treatment decisions in multiple sclerosis - insights from real-world observational studies.Critical analysis on the present methods for brain volume measurements in multiple sclerosis.Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis."No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.Loss of corticospinal tract integrity in early MS disease stages.The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy.SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.Cell-based therapeutic strategies for multiple sclerosis.Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.Advancing trial design in progressive multiple sclerosis.Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.A Fully Automated Pipeline for Normative Atrophy in Patients with Neurodegenerative Disease.Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up.No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study."No evidence of disease activity" - is it an appropriate surrogate in multiple sclerosis?No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.Establishing pathological cut-offs for lateral ventricular volume expansion rates.Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis

P2860

Q26771968-CC6855C3-E050-46F6-BAEE-6DDE2F5510DD Q31134617-76E429A0-9081-4C7F-9C97-D2C693614E3F Q31160866-B1391BD3-9971-4D08-ACDB-1DC24EBF7F33 Q33628626-8CFF8593-392B-4231-B078-93AE4D5CCF3E Q33736193-84EEE5A8-3BAD-4D24-BC14-4458785BDB6C Q33742905-7EFAE5C1-2AA3-47A0-8805-E79AC801782B Q33769234-8C400EA0-3DF4-4745-8FFB-F28A7EC70DEE Q36148189-9E571314-9982-48D3-AEC9-78EE04930055 Q36202826-F011A20B-8086-4FE3-89FF-CAC042F8FA87 Q36293431-FA544CA3-7114-4E4C-81A0-9EEEC1F958AC Q36357501-E6506E48-D770-4D7E-9E1C-514D96752101 Q36400004-4542460E-0136-4EEC-B661-86A2684CB5C2 Q37409279-4B239A00-B2EF-45D9-A259-299A3318B574 Q38606914-39E8F802-564F-4A06-91F9-719DF8EA726B Q38654791-F40E4CD6-B13B-41C0-A261-9E84E88691F7 Q38659598-66FCAB33-69DF-4326-8AEF-65E63B8FFD92 Q38666303-CD3D3132-BE80-4E1F-A0DF-C183F16AD9E1 Q38808604-B6BDD64B-C7B3-4341-A59B-EE90DE303BCB Q38879765-F7651573-82FF-4869-8BB9-848EB3B07F1F Q39021942-AAD0F70F-4F12-490D-B2A2-7669ADB003F4 Q39022643-BE02520B-4D54-45EB-8B9F-120E0BB7F234 Q39459514-44649959-2755-4B03-8F24-872DB416C878 Q40090879-41278C63-88EC-4E7F-9533-B2F897854E99 Q41185260-9B4D2F71-0013-4982-80BD-0FB5A8E0E751 Q41676647-79637654-F2E3-47D3-9BB4-CDE83A07382A Q43375909-B367AAAE-3ECF-4BE8-847B-EF236E4D5ADA Q46861116-3A8AA9B2-5B72-4F4D-B2C6-0EDE7B0876E1 Q47445376-A52E463B-0915-4E7A-9375-D1C9C5786EE3 Q47678330-1FB8210A-D516-4F83-A09D-B27C51E16025 Q47885870-BC93CFDB-439E-462B-AC93-58659B741CDC Q47967210-CA49694E-C0F6-4290-9166-CA340735A95F Q48571910-D8ECFBD2-73D1-4D8F-893B-38E66BE7F132 Q48625365-E52C62D4-8D6D-420E-AB36-51A4208465D7 Q49247807-689FFBC3-6805-4775-A7C7-D69C2E19FDED Q50050892-6B929DE9-9FD6-4619-B31B-A241C4F1C990 Q50956425-5DAB996E-80A6-4944-AB37-49632407D777 Q52567799-E5404A57-0FB1-48CF-AEEC-FB52AD87C0D1 Q52641471-6B0656CE-0B3B-4ABA-95A7-4D344A763390 Q52661563-4E772D6B-1FE6-4DA1-8FF4-A0D2EEE22E83 Q57039929-E01ADDF2-351C-4FBD-82D8-5D29DA385B53

P2860

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.

http://www.wikidata.org/entity/Q35846504

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Inclusion of brain volume loss ...... -remitting multiple sclerosis.

@ast

Inclusion of brain volume loss ...... -remitting multiple sclerosis.

@en

type

label

Inclusion of brain volume loss ...... -remitting multiple sclerosis.

@ast

Inclusion of brain volume loss ...... -remitting multiple sclerosis.

@en

prefLabel

Inclusion of brain volume loss ...... -remitting multiple sclerosis.

@ast

Inclusion of brain volume loss ...... -remitting multiple sclerosis.

@en

P1433

Q35846504-5A6A3E5D-6F4B-472B-B793-5769713EC895

P1476

Q35846504-A2BFEFE7-8676-44DF-928A-A0BCCE889135

P2093

Q35846504-1FE5F01B-BB6F-40B5-BAA8-18ADCDC0F456

Q35846504-384D6555-9AE2-4160-8A28-4322BB88F589

Q35846504-5C3DB4C9-3992-4E4E-AD47-13D736D312D3

Q35846504-78C10565-3070-495F-A303-4B1B4ED22FF1

Q35846504-AD5E3BC4-34E2-4C8D-953D-252CFB011C0D

Q35846504-B8D0B8C1-2268-4DD9-A5AC-8F76843E1869

Q35846504-EB232F8D-5063-4C7C-8569-EBD126EA7ABF

P2860

Q35846504-031D2D95-A119-48AE-BBB1-0ACD69D020DE

Q35846504-0C98FD3D-2EEB-4FB7-A0CE-CD0DF8DD6BE4

Q35846504-296D7ADF-2923-49D1-9C9C-34CCA59026A7

Q35846504-2DB72862-CD85-4644-95A9-D06970D70041

Q35846504-31973E56-597E-4074-8605-88C5C723CDE8

Q35846504-389C2730-85F2-411A-A8E0-6BFA0491B340

Q35846504-4CF5C5FA-FD2E-4F1A-BFC8-997A8FEF4488

Q35846504-5E7F1FBE-5C46-4C0A-9E0D-8AF05E5433B8

Q35846504-622F5A08-69BA-42C1-9E82-40A68BEE423D

Q35846504-639C940D-0E6C-406C-B0E1-9570EAD5D66F

P304

Q35846504-692A9C9E-EB7B-42F0-A99B-580250FFD6B3

P31

Q35846504-7B964EAC-5448-4C01-8BD2-FBF25120518F

P356

Q35846504-1B2F02B5-DC68-4905-9869-AF82B27C28A8

P433

Q35846504-61FC8EA5-D11F-4934-A0AA-A06BE4C87822

P478

Q35846504-BE503BC8-A0E0-4C27-B359-86EEAE54B8C6

P50

Q35846504-05135F18-050C-44F0-9EFE-FD007064F05D

Q35846504-4EA5966E-EB4D-4844-A437-11DE4F00A347

Q35846504-7B2C4A9F-DF7E-4491-9A66-DE96A9E1DBEA

Q35846504-E14E2E8E-857D-400F-A1D3-DDFB742EB30D

P577

Q35846504-0BA0CAD8-6DC6-4455-8596-6531F61EF296

P698

Q35846504-EE8D8932-AC3B-4EE8-9413-A13AAA64A7B2

P921

Q35846504-515FD406-64A0-4DDF-82FC-FB0716A8950D

P932

Q35846504-B890349E-6D04-4540-9A5E-F111A76DEE22

P356

1352458515616701

P1433

Multiple Sclerosis Journal

P1476

Inclusion of brain volume loss ...... -remitting multiple sclerosis.

@en

P2093

Bruce Ac Cree

http://www.w3.org/2001/XMLSchema#string

Daniela Piani Meier

http://www.w3.org/2001/XMLSchema#string

Davorka Tomic

http://www.w3.org/2001/XMLSchema#string

Dieter A Häring

http://www.w3.org/2001/XMLSchema#string

Ernst-Wilhelm Radue

http://www.w3.org/2001/XMLSchema#string

Ludwig Kappos

http://www.w3.org/2001/XMLSchema#string

Mark S Freedman

http://www.w3.org/2001/XMLSchema#string

P2860

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Clinical relevance of brain volume measures in multiple sclerosis.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Association between pathological and MRI findings in multiple sclerosis.

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.

MRI predictors of cognitive outcome in early multiple sclerosis

P304

1297-1305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458515616701

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Nicola De Stefano

P577

2015-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26585439

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

5015759

http://www.w3.org/2001/XMLSchema#string